StockData
Relay Therapeutics, Inc. logo

Relay Therapeutics, Inc. (RLAY) stock

RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 10/30
$16.47−0.80 (-4.63%)

Close on Nov 17, 2026Market cap $3.61BP/E –Yield –

Relay Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Relay Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$212.21M. For fiscal 2025 it was -$235.46M. The highest annual figure on record is -$66.13M in fiscal 2019.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$235.46M–
FY2024Dec 31, 2024-$249.11M–
FY2023Dec 31, 2023-$300.32M–
FY2022Dec 31, 2022-$229.49M–
FY2021Dec 31, 2021-$74.41M–
FY2020Dec 31, 2020-$102.49M–
FY2019Dec 31, 2019-$66.13M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$54.11M–
Q1 FY2026Mar 31, 2026-$51.11M–
Q4 FY2025Dec 31, 2025-$44.87M–
Q3 FY2025Sep 30, 2025-$62.12M–
Q2 FY2025Jun 30, 2025-$55.26M–
Q1 FY2025Mar 31, 2025-$73.21M–
Q4 FY2024Dec 31, 2024-$57.87M–
Q3 FY2024Sep 30, 2024-$75.08M–
Q2 FY2024Jun 30, 2024-$65.83M–
Q1 FY2024Mar 31, 2024-$50.32M–
Q4 FY2023Dec 31, 2023-$89.19M–
Q3 FY2023Sep 30, 2023-$75.40M–
Q2 FY2023Jun 30, 2023-$68.60M–
Q1 FY2023Mar 31, 2023-$67.13M–
Q4 FY2022Dec 31, 2022-$57.08M–
Q3 FY2022Sep 30, 2022-$66.15M–
Q2 FY2022Jun 30, 2022-$57.09M–
Q1 FY2022Mar 31, 2022-$49.17M-205.4%
Q4 FY2021Dec 31, 2021-$39.71M–
Q3 FY2021Sep 30, 2021-$53.20M–
Q2 FY2021Jun 30, 2021-$28.14M–
Q1 FY2021Mar 31, 2021$46.64M–
Q4 FY2020Dec 31, 2020-$35.27M–
Q3 FY2020Sep 30, 2020-$24.04M–
Q2 FY2020Jun 30, 2020-$20.84M–
Q1 FY2020Mar 31, 2020-$22.33M–
Q4 FY2019Dec 31, 2019-$22.76M–
Q3 FY2019Sep 30, 2019-$17.50M–

More Relay Therapeutics figures

See a number that looks wrong?